Literature DB >> 23744869

Diagnosis and treatment of chordoma.

Brian J Williams1, Daniel M S Raper, Erin Godbout, T David Bourne, Daniel M Prevedello, Amin B Kassam, Deric M Park.   

Abstract

Chordoma is a primary bone cancer arising on the midline from the skull base to the sacrum. Diagnosis is often delayed because of insidious onset and nonspecific symptoms. Chordomas appear histologically low-grade but are highly invasive and often recur locally. Management centers primarily on radical en bloc surgical resection when possible. Radiation therapy using protons and/or photons is often necessary because complete resection is seldom possible due to critical location and invasion of the cancer cells into surrounding structures. No approved medical therapy exists. The high rate of recurrence is reflected by a median survival of 6 to 7 years. This article reviews the clinical management of chordoma and discusses ongoing research in the field.

Entities:  

Mesh:

Year:  2013        PMID: 23744869     DOI: 10.6004/jnccn.2013.0089

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  19 in total

1.  Analysis of variants at LGALS3 single nucleotide polymorphism loci in skull base chordoma.

Authors:  Kaibing Tian; Liang Wang; Ke Wang; Junpeng Ma; Da Li; Yang Yang; Guijun Jia; Zhen Wu; Liwei Zhang; Junting Zhang
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

2.  Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.

Authors:  Achim H Bell; Franco DeMonte; Shaan M Raza; Laurence D Rhines; Claudio E Tatsui; Victor G Prieto; Gregory N Fuller; Diana Bell
Journal:  Virchows Arch       Date:  2017-08-27       Impact factor: 4.064

3.  Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.

Authors:  A Alholle; A T Brini; J Bauer; S Gharanei; S Niada; A Slater; D Gentle; E R Maher; L Jeys; R Grimer; V P Sumathi; F Latif
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

4.  Combination of PARP inhibitor and temozolomide to suppress chordoma progression.

Authors:  Xiaoyu Cao; Yanxin Lu; Yang Liu; Yiqiang Zhou; Hua Song; Wei Zhang; Dionne Davis; Jing Cui; Shuyu Hao; Jinkyu Jung; Qixin Wu; Deric M Park; Chunzhang Yang
Journal:  J Mol Med (Berl)       Date:  2019-06-14       Impact factor: 4.599

5.  A 69-year-old presenting with musculoskeletal low back pain: a case of lumbosacral chordoma.

Authors:  Shawn P Williams; Bernard Beckerman; Maria Elena Piña Fonti
Journal:  J Chiropr Med       Date:  2014-06

6.  STAT3 Inhibition as a Therapeutic Strategy for Chordoma.

Authors:  Anthony C Wang; John H Owen; Waleed M Abuzeid; Shawn L Hervey-Jumper; Xiaobing He; Mikel Gurrea; Meijuan Lin; David B Altshuler; Richard F Keep; Mark E Prince; Thomas E Carey; Xing Fan; Erin L McKean; Stephen E Sullivan
Journal:  J Neurol Surg B Skull Base       Date:  2016-05-31

7.  Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Authors:  Shuyu Hao; Hua Song; Wei Zhang; Ashlee Seldomridge; Jinkyu Jung; Amber J Giles; Marsha-Kay Hutchinson; Xiaoyu Cao; Nicole Colwell; Adrian Lita; Mioara Larion; Dragan Maric; Mones Abu-Asab; Martha Quezado; Tamalee Kramp; Kevin Camphausen; Zhengping Zhuang; Mark R Gilbert; Deric M Park
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

8.  The embryonic transcription factor Brachyury confers chordoma chemoresistance via upregulating CA9.

Authors:  Jiao Jian; Nanzhe Zhong; Dongjie Jiang; Lei Li; Yan Lou; Wang Zhou; Su Chen; Jianru Xiao
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

9.  A rare case of chordoma presenting as a Pancoast tumor.

Authors:  Philip T Sobash; Krishna Vedala; Daniel Alfano; Heather Pinckard-Dover; Jason L Muesse; Raman Desikan
Journal:  Rare Tumors       Date:  2021-07-02

10.  Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.

Authors:  Dae-Hee Lee; Ying Zhang; Amin B Kassam; Myung-Jin Park; Paul Gardner; Daniel Prevedello; Stephanie Henry; Craig Horbinski; Jan H Beumer; Hussein Tawbi; Brian J Williams; Mark E Shaffrey; Merrill J Egorin; Roger Abounader; Deric M Park
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.